Neuropore Therapies Inc, based in San Diego, CA, is a biopharmaceutical company dedicated to discovering innovative therapeutics that target the underlying causes of neurodegenerative diseases, with the aim of halting their progression. Their current clinical trials include the Phase 2 study of UCB0599 in patients with early-stage Parkinson's disease, and they have recently received a $4.8M grant from The Michael J. Fox Foundation for Parkinson's Research to support the development of their TLR2 program.
With a team of experts and strategic partnerships with corporate foundations and academic institutions, Neuropore Therapies is well-positioned to make significant advancements in the field of neurodegenerative disease research. Their publications highlight the positive effects of their small molecule targeting -synuclein in a transgenic mouse model of Parkinson's disease, showcasing their commitment to finding potential therapeutic solutions. Through their dedication and cutting-edge approach, Neuropore Therapies is poised for success in their mission to combat neurodegenerative diseases.
Generated from the website